Detection of endothelial cell‐reactive immunoglobulin in patients with anti‐phospholipid antibodies

British Journal of Haematology

Volumn 79, Issue 4, 1991, Pages 595-605

  McCrae, Keith R ^a   DeMichele, Angela ^a   Samuels, Philip ^a,b   Roth, Denise ^a   Kuo, Alice ^a   Meng, Qiang‐hua ^a,c   Rauch, Joyce ^a,c   Cines, Douglas B ^a  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; PHOSPHOLIPID ANTIBODY; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; PRIORITY JOURNAL; THROMBOSIS;

ANTIBODIES; ANTIPHOSPHOLIPID SYNDROME; CARDIOLIPINS; ENDOTHELIUM, VASCULAR; HUMAN; IMMUNOGLOBULINS; LUPUS COAGULATION INHIBITOR; PHOSPHOLIPIDS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 0026354068     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.1991.tb08087.x     Document Type: Article

References (68)

1. Primary anti‐phospholipid syndrome
2. Preparation and use of liposomes in immunological studies
3. The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid
4. Predisposing factors to thrombosis in systemic lupus erythematous
5. Platelet binding properties of monoclonal lupus autoantibodies produced by human hybridomas
6. Lupus anticoagulant in the acquired immunodeficiency syndrome
7. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant
8. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants
9. Obstetric complications associated with the lupus anticoagulant
10. Indications of vascular endothelium dysfunction in systemic lupus erythematosus
11. Anticardiolipin antibodies associated with HTLV III infection
12. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells‐‐‐inhibition of thrombomodulin‐dependent protein C activation
13. Lupus’ anticoagulant and thrombosis‐possible role of inhibition of prostacyclin formation
14. Cofactor dependent and cofactor‐independent anticardiolipin antibodies
15. Presence of complement‐fixing anti‐endothelial cell antibodies in systemic lupus erythematosus
16. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome
17. 32P
18. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants. (Abstract)
19. Second trimester fetal monitoring and preterm delivery in pregnancies with systemic lupus eythematosus and/or circulating anticoagulant
20. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid coated polystyrene column
21. Thromboembolism in patients with the ‘lupus type’ circulating anticoagulant
22. Possible relationship between lupus inhibitor and recurrent abortion in young women. (Letter)
23. Anti‐prothrombin antibodies and the lupus anticoagulant
24. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin
25. Anticardiolipin antibodies directed not to cardiolipin but to a plasma cofactor
26. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants
27. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
28. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test
29. Anticardiolipin antibody testing; the need for standardization. (Letter)
30. Anti‐endothelial cell antibodies: detection and characterization using a cellular enzyme‐linked immunosorbent assay
31. Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis
32. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets
33. Complement proteins C5b‐9 induce secretion of high molecular weight multimers of endothelial cell von Willebrand factor and translocation of granule membrane protein GMP‐140 to the cell surface
34. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria
35. Cleavage of structural head proteins during the assembly of the head of bacteriophage T4
36. IgG binding to endothelial cells in systemic lupus erythematosus
37. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus
38. Measurement of anti‐cardiolipin antibodies by an enzyme‐linked immunosorbent assay (ELISA): standardization and quantitation of results
39. Lupus anticoagulant in pregnancy
40. Fetal survival after prednisone suppression of maternal lupus anticoagulant
41. Impaired catalytic function of activated protein C: a new in‐vitro manifestation of lupus anticoagulant
42. Circulating anticoagulants: a study of 40 cases and a review of the literature
43. Influence of fusion ratio and cell‐plating density on production of human‐human hybridomas secreting anti‐DNA autoantibodies from patients with systemic lupus erythematosus
44. 2‐glycoprotein 1 (apolipoprotein H)
45. The interaction of lupus anticoagulants with human platelets. (Abstract)
46. Thrombosis in patients with the lupus anticoagulant
47. 2‐glycoprotein‐1 inhibits the release reaction of human platelets during ADP‐induced aggregation
48. 2‐glycoprotein. I
49. Anticardiolipin antibodies in patients with primary immunodeficiency diseases
50. Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies
51. Distinguishing plasma lupus anticoagulants from anti‐factor antibodies using hexagonal (II) phase phospholipids
52. Measurement and characterization of circulating anti‐endothelial cell IgG in connective tissue diseases
53. Natural anticoagulant mechanisms
54. A clinical study of the lupus anticoagulant
55. Lupus anticoagulant induces a selective defect in thrombin‐mediated endothelial prostacyclin release and platelet aggregation
56. 2‐glycoprotein 1 to platelets: effect of adenylate cyclase activity
57. Hybridoma lupus autoantibodies can bind major cytoskeletal filaments in the absence of DNA‐binding activity
58. Evidence that cell surface heparan sulfate is involved in the high affinity thrombin binding to cultured porcine aortic endothelial cells
59. Confidence intervals for reporting results of clinical trials
60. The 1982 revised criteria for the diagnosis of SLE
61. Antibody and immune complexes induce tissue factor production by human endothelial cells
62. Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specificity
63. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin procedure with a new platelet neutralization procedure
64. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant
65. Anticardiolipin response in acute infections
66. Relationship between anti‐cardiolipin and anti‐endothelial cell antibodies in systemic lupus erythematosus
67. Biosynthesis of von Willebrand protein by human endothelial cells
68. Lupus anticoagulant inhibition of in‐vitro prostacyclin release is associated with a thrombosis‐prone subset of patients